Island Pharmaceuticals (ASX:ILA) Phase 2a/b PROTECT clinical trial update

Island Pharmaceuticals Ltd (ASX:ILA) has successfully dosed all subjects in the Phase 2a component of its ISLA-101 Phase 2a/b clinical trial in dengue fever. The trial, known as PROTECT, is a pioneering clinical trial design aimed at examining a dengue infection in a controlled setting.

Executive Commentary on Phase 2a/b PROTECT Clinical Trial

Dosing the Phase 2a subjects in this powerful Phase 2 PROTECT clinical trial is a pivotal moment for Island. We are weeks away from understanding the potential impact of our drug ISLA-101 on dengue fever. As the first company in the world to investigate an agent as both a prophylactic and therapeutic against dengue in a clinical setting with a challenge virus, we are proud to be conducting this innovative trial to find a preventative and/or treatment for this devastating virus, at a time when infection rates are rapidly growing around the globe.

Summary of Island Pharmaceuticals (ASX:ILA) Announcement

Island Pharmaceuticals Ltd (ASX:ILA) has achieved a significant milestone by dosing all subjects in the Phase 2a component of its ISLA-101 Phase 2a/b clinical trial in dengue fever. The company's CEO and Managing Director, Dr David Foster, highlighted the importance of this step and the potential impact of ISLA-101 on dengue fever. The Phase 2a/b PROTECT clinical trial is a pioneering effort to investigate a potential countermeasure for dengue virus, addressing the unmet need for antiviral therapeutics. Island is also set to conduct an investor webinar to discuss the latest trial developments and provide an overview of recent company developments, including the proposed acquisition of antiviral molecule, galidesivir. The company's lead asset, ISLA-101, holds the potential for FDA approval, which could lead to obtaining a 'Priority Review Voucher' and expedite the FDA approval process for a new drug or sell the voucher in a secondary market. Island's focus on addressing infectious diseases and unmet medical needs reflects its commitment to making a meaningful impact in the healthcare sector.